Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 9/30/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $9 | $11 | $47 | $48 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $1 | $0 |
| Enterprise Value | $9 | $11 | $48 | $48 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$1 | -$5 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$1 | -$5 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.009 | -0.008 | -0.057 | -0.011 |
| % Growth | -18.2% | 86.4% | -407.1% | – |
| Operating Cash Flow | -$1 | – | -$1 | -$1 |
| Capital Expenditures | $0 | – | $0 | -$0 |
| Free Cash Flow | -$1 | – | -$1 | -$1 |